Researchers introduced a new tool designed to track unintended CRISPR edits and quantify their effects at the level of individual cells. The approach targets a key bottleneck for genome editing: off-target outcomes that can be missed by bulk assays. As CRISPR platforms spread into preclinical development and increasingly into therapeutic programs, measuring edit purity and biological consequences becomes central for both safety and efficacy. A single-cell lens helps separate mixed populations, improving the ability to assess how rare off-target events may contribute to phenotype. The method adds to the toolbox biotechs use for validation work in areas like preclinical lead optimization, IND-enabling studies, and mechanism-of-action confirmation.
Get the Daily Brief